PixCell Medical

• Booth: 4362

PixCell Medical, an innovator of rapid hematology testing solutions at the point of care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use – the HemoScreen™. This portable, easy-to-use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. This facilitates fast diagnostic results and data-driven disease management decisions. Leveraging a cutting-edge disposable cartridge preloaded with all necessary reagents, HemoScreen’s unique AI-powered Viscoelastic Focusing technology enables improved medical outcomes and patient quality of life while substantially reducing costs for healthcare providers.

 Press Releases

• PixCell Medical Partners with Medline, Henry Schein, and Fisher Scientific (Apr 08, 2024)
  PixCell Medical, a leading provider of innovative point-of-care diagnostic solutions, is pleased to announce a strategic distribution partnership with Medline, adding to the partnership agreements with Henry Schein and Thermo Fisher Scientific signed in recent months. These agreements mark a significant milestone in PixCell Medical's expansion strategy, as the company continues to enhance accessibility to its flagship product, the HemoScreen point-of-care Complete Blood Count (CBC) analyzer, across the United States.
  
  Medline Industries, a prominent medical supply distributor, will play a key role in ensuring seamless access to PixCell Medical's innovative diagnostic technology for healthcare facilities of all sizes. The partnership with Henry Schein, a global leader in healthcare solutions, will leverage the company's extensive distribution network to make the HemoScreen analyzer readily available to healthcare professionals nationwide.  Additionally, Thermo Fisher Scientific, renowned for its scientific expertise and comprehensive product offerings, will contribute to broadening the reach of the HemoScreen analyzer within the scientific research and laboratory community.
  
  "We are thrilled to join forces with Henry Schein, Medline, and Thermo Fisher Scientific to bring the HemoScreen point-of-care CBC analyzer to healthcare providers and laboratories throughout the United States," said Guy Frak, CCO of PixCell Medical. "These strategic partnerships align with our commitment to advancing patient care by delivering accurate and timely diagnostic solutions directly to the point of need."
  
  The HemoScreen analyzer offers rapid and precise CBC results within minutes, empowering healthcare professionals with actionable insights for timely diagnosis and treatment decisions at the point of treatment. With its compact design and user-friendly interface, HemoScreen enhances efficiency and workflow optimization in various healthcare settings, including clinics, emergency departments, and laboratories.
  
  These recent key distribution agreements underscore PixCell Medical's commitment to fostering strategic partnerships that drive market penetration and enhance customer reach. Through these collaborations, PixCell Medical remains dedicated to advancing healthcare delivery by making cutting-edge diagnostic technology accessible and affordable across diverse healthcare settings.
  
  About PixCell Medical
  
  PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use – the HemoScreen.
  
  The portable, easy-to-use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. Leveraging a patented, disposable cartridge preloaded with all necessary reagents, the company's unique Viscoelastic Focusing technology, and AI-powered machine vision, PixCell enables improved medical outcomes and patient quality of life and reduces costs for healthcare providers.
  
  For more information: www.pixcell-medical.com
  
  Follow PixCell Medical on LinkedIn and Twitter.

• Research Team at UNC Validates PixCell Medical's HemoScreen as Game-Changer (Apr 08, 2024)

  A groundbreaking study conducted by a University of North Carolina (UNC) research team has unveiled compelling evidence supporting the adoption of PixCell Medical's FDA-cleared Point-of-Care 5-part differential CBC analyzer, as the premier choice for psychiatric treatment and monitoring, specifically in the context of Clozapine therapy. The research, which evaluated three point-of-care instruments for complete blood count analysis, has positioned HemoScreen as the optimal solution for the management of Clozapine treatment.

  Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC). To find a clinically viable and simple-to-use CBC analyzer for frequent near-patient testing, a UNC research team assessed three CBC analyzers: Sight OLO, PixCell HemoScreen, and Sysmex pocH-100i, comparing them against the ADVIA 2120i and manual differential methods.

  HemoScreen exhibited remarkable precision, outperforming other instruments, and demonstrating exceptional accuracy. Notably, HemoScreen excelled in clinical concordance, achieving a rate of 89.5% at medical decision thresholds for ANC, surpassing the other POC devices. This establishes HemoScreen as the most reliable choice in Clozapine therapy management.

  Dr. Yaara Ben Yosef, PixCell Medical's director of clinical affairs, emphasized; "This research demonstrates that HemoScreen is the superior choice for monitoring patients on Clozapine therapy. The high clinical concordance and exceptional accuracy of the HemoScreen make it an indispensable tool for healthcare professionals in managing the potential risks associated with Clozapine treatment."

  Additionally, HemoScreen's ability to sample blood via a fingerstick (direct capillary sampling) offers a significant advantage, especially for psychiatry patients requiring weekly or monthly CBC testing as part of their Clozapine treatment management. The uniquely simple blood collection method and minimal discomfort of HemoScreen's simple sampling procedure with near-patient on-the-spot results provide substantial benefits for treatment adherence and positive outcomes.

  This groundbreaking research cements PixCell Medical's HemoScreen as the gold standard for complete blood count analysis in Clozapine therapy. Healthcare providers can confidently rely on HemoScreen to ensure the safety and efficacy of Clozapine treatment for patients with treatment-resistant schizophrenia.
   

  About PixCell Medical
  PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use –the HemoScreen™. The portable, easy-to-use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. Leveraging a patented, disposable cartridge preloaded with all necessary reagents, the company's unique Viscoelastic Focusing technology, and AI-powered machine vision, PixCell enables improved medical outcomes and patient quality of life and reduces costs for healthcare providers.

  (*) PixCell Medical is not associated with the University of North Carolina, nor did it support, assist, or contribute in any way to this study or anyone on the team. It was not informed before or during conducting the study and had no impact in any way on its conclusions.
   

  For more information: www.pixcell-medical.com

  Follow PixCell Medical on LinkedIn and Twitter.

• FDA Clears PixCell Medical's HemoScreen™ Point of Care CBC for Direct Cap (Apr 08, 2024)

  PixCell Medical, an innovator of rapid hematology testing solutions at the point of care (POC), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for direct capillary sampling with the HemoScreen 5-part differential CBC analyzer, substantially simplifying blood sampling and minimizing the pre-analytical process.

  HemoScreen has been FDA-cleared for point-of-care use with venous and capillary blood since 2018, and to date has been the only 5-part differential CBC analyzer cleared for POC use. The recent clearance enables collection of a sample directly from the finger without an intermediate tube. Direct sampling is a significant advantage over other blood count devices, as it enables unparalleled ease of capillary blood collection that does not require a phlebotomist or physician, requires much less expertise, is quicker, painless, and is much less prone to pre-analytical errors.

  This recent FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer with its proprietary single-use reagent cartridge, automatic sample preparation, and exceptionally simple blood collection procedure.

  "This latest clearance is a major milestone and a profound vote of confidence, allowing HemoScreen users to utilize an exceptionally simple sampling procedure" states Dr. Avishay Bransky, PixCell Medical co-founder and CEO. "With the clearance to use direct capillary sampling, HemoScreen has become a true game changer in POC hematology, making it even easier to operate, negating pre-analytical challenges common with other CBC analyzers in the market, and increasing diagnostic throughput."
   

  About PixCell Medical

  PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use –the HemoScreen™. The portable, easy-to-use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. This facilitates fast diagnostic results and data-driven disease management decisions. Leveraging a patented, disposable cartridge preloaded with all necessary reagents, the company's unique Viscoelastic Focusing technology, and AI-powered machine vision, PixCell enables improved medical outcomes and patient quality of life and reduces costs for healthcare providers.

  For more information: www.pixcell-medical.com
  Follow PixCell Medical on LinkedIn and Twitter.